Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
August 12, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Enrollment Continues for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD; Topline Data Expected First Half of 2020 Pipeline Expanded in Addiction Medicine with Cocaine Antidote TNX-1300...
Tonix Pharmaceuticals Announces Director Stepping Down
August 02, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Patrick Grace stepped down from the Company’s Board of Directors, effective...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
July 25, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S....
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
July 18, 2019 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 18, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the closing of an...
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
July 16, 2019 08:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the pricing of an...
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
June 13, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small...
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
May 30, 2019 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small molecules...
Tonix Pharmaceuticals to Present at BIO 2019 International Convention
May 28, 2019 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer...
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
May 23, 2019 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 2 Program Granted Breakthrough Therapy Designation by FDA Emergency Room Visits for Cocaine Abuse Total More than 500,000 Annually in U.S. NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) --...
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
May 22, 2019 16:19 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer...